| scholarly article | Q13442814 |
| P2093 | author name string | David S Alberts | |
| Joanne M Jeter | |||
| P2860 | cites work | Cancer statistics, 2010 | Q27860525 |
| Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial | Q28217835 | ||
| Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial | Q28244429 | ||
| Long-term results of tamoxifen prophylaxis for breast cancer--96-month follow-up of the randomized IBIS-I trial | Q28289262 | ||
| Prevention of skin cancer in xeroderma pigmentosum with the use of oral isotretinoin | Q28294912 | ||
| Phase III trial of accelerated hyperfractionation with or without difluromethylornithine (DFMO) versus standard fractionated radiotherapy with or without DFMO for newly diagnosed patients with glioblastoma multiforme | Q31861401 | ||
| Phase II trials of alpha-difluoromethylornithine, an inhibitor of polyamine synthesis, in advanced small cell lung cancer and colon cancer. | Q33445360 | ||
| Phase I trial and pharmacokinetic studies of alpha-difluoromethylornithine--an inhibitor of polyamine biosynthesis | Q33478177 | ||
| A randomized, double-blind, placebo-controlled phase 3 skin cancer prevention study of {alpha}-difluoromethylornithine in subjects with previous history of skin cancer | Q33584310 | ||
| Development of difluoromethylornithine (DFMO) as a chemoprevention agent. | Q33650043 | ||
| Polyamines and cancer: old molecules, new understanding | Q34362757 | ||
| Overview of the main outcomes in breast-cancer prevention trials | Q35057371 | ||
| A phase III skin cancer chemoprevention study of DFMO: long-term follow-up of skin cancer events and toxicity | Q36457059 | ||
| Randomized prospective phase III trial of difluoromethylornithine vs placebo in preventing recurrence of completely resected low risk superficial bladder cancer | Q36524475 | ||
| The effect of difluoromethylornithine on decreasing prostate size and polyamines in men: results of a year-long phase IIb randomized placebo-controlled chemoprevention trial | Q36836192 | ||
| Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial | Q36924101 | ||
| Phase I chemoprevention study of difluoromethylornithine in subjects with organ transplants | Q39121478 | ||
| Polyamine metabolism and its importance in neoplastic growth and a target for chemotherapy | Q39599826 | ||
| Induction of mouse epidermal ornithine decarboxylase activity and DNA synthesis by ultraviolet light | Q41486705 | ||
| Skin cancer is among the most costly of all cancers to treat for the Medicare population | Q42438312 | ||
| Melanoma incidence and mortality among US whites, 1969-1999. | Q43469137 | ||
| Modulation of biologic endpoints by topical difluoromethylornithine (DFMO), in subjects at high-risk for nonmelanoma skin cancer. | Q43860642 | ||
| A phase II breast cancer chemoprevention trial of oral alpha-difluoromethylornithine: breast tissue, imaging, and serum and urine biomarkers | Q44175750 | ||
| Evaluation of alpha-difluoromethylornithine as a potential chemopreventive agent: tolerance to daily oral administration in humans. | Q44466339 | ||
| Effect of alpha-difluoromethylornithine on rectal mucosal levels of polyamines in a randomized, double-blinded trial for colon cancer prevention | Q44788424 | ||
| Correlation of the inhibition by retinoids of tumor promoter-induced mouse epidermal ornithine decarboxylase activity and of skin tumor promotion | Q44838882 | ||
| Results of a phase II double-blinded randomized clinical trial of difluoromethylornithine for cervical intraepithelial neoplasia grades 2 to 3. | Q45238922 | ||
| Treatment of recurrent gliomas with eflornithine | Q48431401 | ||
| Phase I-II clinical trial with alpha-difluoromethylornithine--an inhibitor of polyamine biosynthesis. | Q50572232 | ||
| Evaluation of difluoromethylornithine for the chemoprevention of Barrett's esophagus and mucosal dysplasia. | Q51548469 | ||
| Phase III randomized study of postradiotherapy chemotherapy with alpha-difluoromethylornithine-procarbazine, N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosurea, vincristine (DFMO-PCV) versus PCV for glioblastoma multiforme. | Q54032299 | ||
| Chemopreventive efficacy of topical difluoromethylornithine and/or triamcinolone in the treatment of actinic keratoses analyzed by karyometry. | Q55518257 | ||
| Randomized phase I chemoprevention dose-seeking study of alpha-difluoromethylornithine | Q70672625 | ||
| Alpha-difluoromethylornithine as treatment for metastatic breast cancer patients | Q73253472 | ||
| Chemoprevention of human actinic keratoses by topical 2-(difluoromethyl)-dl-ornithine | Q73355841 | ||
| P433 | issue | 12 | |
| P304 | page(s) | 1341-1344 | |
| P577 | publication date | 2012-12-01 | |
| P1433 | published in | Cancer Prevention Research | Q2665103 |
| P1476 | title | Difluoromethylornithine: the proof is in the polyamines | |
| P478 | volume | 5 |
| Q35388587 | A simple and sensitive assay for eflornithine quantification in rat brain using pre-column derivatization and UPLC-MS/MS detection |
| Q48506495 | Alpha-Difluoromethylornithine, an Irreversible Inhibitor of Polyamine Biosynthesis, as a Therapeutic Strategy against Hyperproliferative and Infectious Diseases |
| Q39140722 | Cytotoxicity of 1,4-diamino-2-butanone, a putrescine analogue, to RKO cells: mechanism and redox imbalance |
| Q38765477 | Difluoromethylornithine in cancer: new advances |
| Q36168155 | Non-canonical Hedgehog/AMPK-Mediated Control of Polyamine Metabolism Supports Neuronal and Medulloblastoma Cell Growth |
| Q50100821 | Polyamines and Cancer |
| Q42085336 | Say what? The activity of the polyamine biosynthesis inhibitor difluoromethylornithine in chemoprevention is a result of reduced thymidine pools? |
Search more.